Under the terms of the pact, the partners will integrate Translational's pharmacogenetics knowledgebase and interpretation platform with Xifin's laboratory information system.
The company reported $2.22 billion in second quarter revenues, with $620.8 million attributable to the Covance acquisition.
The CDx test will be developed to identify best responders for Apogenix's APG101 for treating solid tumors and malignant hematological diseases.
A Hermes Pardini Institute researcher described how a gene panel test for breast cancer uncovered variants of unknown significance and how new data changed their significance.
The Xpert Omni platform will launch in 2016 running Cepheid test cartridges on a compact battery-operated device that is anticipated to cost less than $3,000.
The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.
Jun Wang, the chief executive of BGI, has stepped down.
The New York Times' George Johnson muses on cancer's roots in multicellularity.
In PLOS this week: locus linked to non-syndromic hearing loss, phylogenetic relationships of Klebsiella pneumoniae isolates, and more.